Skip to main content
Erschienen in: International Journal of Colorectal Disease 12/2014

01.12.2014 | Original Article

The timing of surgery after preoperative short-course S-1 chemoradiotherapy with delayed surgery for T3 lower rectal cancer

verfasst von: Naohito Beppu, Nagahide Matsubara, Masashi Noda, Tomoki Yamano, Hiroshi Doi, Norihiko Kamikonya, Naoki Yamanaka, Hidenori Yanagi, Naohiro Tomita

Erschienen in: International Journal of Colorectal Disease | Ausgabe 12/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The purpose of this study was to analyze the influence of variations in clinical practice regarding the timing of surgery with short-course chemoradiotherapy with delayed surgery (SCRT-delay) for lower rectal cancer.

Methods

A total of 171 patients with T3 N0-2 lower rectal cancer treated with SCRT-delay (25 Gy/10 fractions/5 days (S-1); days 1–10) were retrospectively evaluated. The median waiting period of 30 days was used as a discriminator (group A: waiting period, ≤30 days; group B: waiting period, ≥31 days). Preoperative treatment responses and oncological outcomes were analyzed.

Results

The mean waiting periods for groups A and B were 24.4 ± 5.3 and 41.4 ± 12.3 days, respectively. There were no statistically significant differences between the two groups in any of the clinical variables. The clinicopathological outcomes were as follows: T downstaging (43.5 vs 37.2 %; p = 0.400), negative yp N (67.1 vs 75.6 %; p = 0.218), pCR (7.1 vs 1.2 %; p = 0.119). The 5-year local recurrence-free survival (89.3 vs 87.6 %; p = 0.956), the recurrence-free survival (82.2 vs 78.8 %; p = 0.662), and the overall survival (88.5 vs 84.4 %; p = 0.741), all of which were similar between the two groups.

Conclusions

The longer waiting period did not increase the tumor downstaging and not improve the oncological outcomes for T3 lower rectal cancer treated with SCRT-delay. In addition, considering that the impaired leukocyte response occurred during the sub-acute period, any time after the sub-acute period (day 12) up to 30 days after radiotherapy would be a suitable waiting period.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat (1997) Swedish Rectal Cancer Trial: improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish Rectal Cancer Trial. N Engl J Med 336:980–987 (1997) Swedish Rectal Cancer Trial: improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish Rectal Cancer Trial. N Engl J Med 336:980–987
2.
Zurück zum Zitat Birgisson H, Paahlman L, Gunnarsson U et al (2005) Adverse effects of preoperative radiation therapy for rectal cancer: long-term follow-up of the Swedish Rectal Cancer Trial. J Clin Oncol 23:8697–8705PubMedCrossRef Birgisson H, Paahlman L, Gunnarsson U et al (2005) Adverse effects of preoperative radiation therapy for rectal cancer: long-term follow-up of the Swedish Rectal Cancer Trial. J Clin Oncol 23:8697–8705PubMedCrossRef
3.
Zurück zum Zitat Schmoll HJ, Van Cutsem E, Stein A et al (2012) ESMO consensus guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol 23:2479–2516PubMedCrossRef Schmoll HJ, Van Cutsem E, Stein A et al (2012) ESMO consensus guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol 23:2479–2516PubMedCrossRef
4.
Zurück zum Zitat Minsky BD (2012) Short-course radiation versus long-course chemoradiation for rectal cancer: making progress. J Clin Oncol 30:3777–3778PubMedCrossRef Minsky BD (2012) Short-course radiation versus long-course chemoradiation for rectal cancer: making progress. J Clin Oncol 30:3777–3778PubMedCrossRef
5.
Zurück zum Zitat Pettersson D, Holm T, Iversen H, Blomqvist L, Glimelius B, Martling A (2012) Preoperative short-course radiotherapy with delayed surgery in primary rectal cancer. Br J Surg 99:577–583PubMedCrossRef Pettersson D, Holm T, Iversen H, Blomqvist L, Glimelius B, Martling A (2012) Preoperative short-course radiotherapy with delayed surgery in primary rectal cancer. Br J Surg 99:577–583PubMedCrossRef
6.
Zurück zum Zitat Hatfield P, Hingorani M, Radhakrishna G et al (2009) Short-course radiotherapy, with elective delay prior to surgery, in patients with unresectable rectal cancer who have poor performance status or significant co-morbidity. Radiother Oncol 92:210–214PubMedCrossRef Hatfield P, Hingorani M, Radhakrishna G et al (2009) Short-course radiotherapy, with elective delay prior to surgery, in patients with unresectable rectal cancer who have poor performance status or significant co-morbidity. Radiother Oncol 92:210–214PubMedCrossRef
7.
Zurück zum Zitat Fukushima M, Sakamoto K, Sakata M, Nakagawa F, Saito H et al (2010) Gimeracil, a component of S-1, may enhance the antitumor activity of X-ray irradiation in human cancer xenograft models in vivo. Oncol Rep 24:1307–1313PubMed Fukushima M, Sakamoto K, Sakata M, Nakagawa F, Saito H et al (2010) Gimeracil, a component of S-1, may enhance the antitumor activity of X-ray irradiation in human cancer xenograft models in vivo. Oncol Rep 24:1307–1313PubMed
8.
Zurück zum Zitat Doi H, Beppu N, Odawara S et al (2013) Neoadjuvant short-course hyperfractionated accelerated radiotherapy (SC-HART) combined with S-1 for locally advanced rectal cancer. J Radiat Res 54:1118–1124PubMedCentralPubMedCrossRef Doi H, Beppu N, Odawara S et al (2013) Neoadjuvant short-course hyperfractionated accelerated radiotherapy (SC-HART) combined with S-1 for locally advanced rectal cancer. J Radiat Res 54:1118–1124PubMedCentralPubMedCrossRef
9.
Zurück zum Zitat Park IJ, You YN, Agarwal A et al (2012) Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. J Clin Oncol 30:1770–1776PubMedCentralPubMedCrossRef Park IJ, You YN, Agarwal A et al (2012) Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. J Clin Oncol 30:1770–1776PubMedCentralPubMedCrossRef
10.
Zurück zum Zitat Agarwal A, Chang GJ, Hu CY et al (2013) Quantified pathologic response assessed as residual tumor burden is a predictor of recurrence-free survival in patients with rectal cancer who undergo resection after neoadjuvant chemoradiotherapy. Cancer 119:4231–4241PubMedCrossRef Agarwal A, Chang GJ, Hu CY et al (2013) Quantified pathologic response assessed as residual tumor burden is a predictor of recurrence-free survival in patients with rectal cancer who undergo resection after neoadjuvant chemoradiotherapy. Cancer 119:4231–4241PubMedCrossRef
11.
Zurück zum Zitat Rodel C, Martus P, Papadoupolos T et al (2005) Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 23:8688–8696PubMedCrossRef Rodel C, Martus P, Papadoupolos T et al (2005) Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 23:8688–8696PubMedCrossRef
12.
Zurück zum Zitat Kotera H, Kusunoki M, Yanagi H, Yamamura T, Utsunomiya J (1997) The regrowth of rectal adenocarcinoma after pre-operative radiotherapy with a report of two cases. Hepatogastroenterology 44:394–397PubMed Kotera H, Kusunoki M, Yanagi H, Yamamura T, Utsunomiya J (1997) The regrowth of rectal adenocarcinoma after pre-operative radiotherapy with a report of two cases. Hepatogastroenterology 44:394–397PubMed
13.
Zurück zum Zitat Japanese Society for Cancer of the Colon and Rectum (2006) General rules for clinical and pathological studies on cancer of the colon, rectum, and anus, 7th edn. Kanehara Shuppan, Tokyo Japanese Society for Cancer of the Colon and Rectum (2006) General rules for clinical and pathological studies on cancer of the colon, rectum, and anus, 7th edn. Kanehara Shuppan, Tokyo
14.
Zurück zum Zitat Fokstuen T, Holm T, Glimelius B (2009) Postoperative morbidity and mortality in relation to leukocyte counts and time to surgery after short-course preoperative radiotherapy for rectal cancer. Radiother Oncol 93:293–297PubMedCrossRef Fokstuen T, Holm T, Glimelius B (2009) Postoperative morbidity and mortality in relation to leukocyte counts and time to surgery after short-course preoperative radiotherapy for rectal cancer. Radiother Oncol 93:293–297PubMedCrossRef
15.
Zurück zum Zitat Pettersson D, Glimelius B, Iversen H, Johansson H, Holm T, Martling A (2013) Impaired postoperative leucocyte counts after preoperative radiotherapy for rectal cancer in the Stockholm III Trial. Br JSurg 100:969–975CrossRef Pettersson D, Glimelius B, Iversen H, Johansson H, Holm T, Martling A (2013) Impaired postoperative leucocyte counts after preoperative radiotherapy for rectal cancer in the Stockholm III Trial. Br JSurg 100:969–975CrossRef
16.
Zurück zum Zitat Marsh Rde W, George TJ, Siddiqui T et al (2010) A phase II trial of neoadjuvant capecitabine combined with hyperfractionated accelerated radiation therapy in locally advanced rectal cancer. Am J Clin Oncol 33:251–256PubMed Marsh Rde W, George TJ, Siddiqui T et al (2010) A phase II trial of neoadjuvant capecitabine combined with hyperfractionated accelerated radiation therapy in locally advanced rectal cancer. Am J Clin Oncol 33:251–256PubMed
17.
Zurück zum Zitat Viani GA, Stefano EJ, Soares FV et al (2011) Evaluation of biologic effective dose and schedule of fractionation for preoperative radiotherapy for rectal cancer: meta-analyses and metaregression. Int J Radiat Oncol Biol Phys 80:985–991PubMedCrossRef Viani GA, Stefano EJ, Soares FV et al (2011) Evaluation of biologic effective dose and schedule of fractionation for preoperative radiotherapy for rectal cancer: meta-analyses and metaregression. Int J Radiat Oncol Biol Phys 80:985–991PubMedCrossRef
18.
Zurück zum Zitat Gérard JP, Conroy T, Bonnetain F et al (2006) Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 24:4620–4625PubMedCrossRef Gérard JP, Conroy T, Bonnetain F et al (2006) Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 24:4620–4625PubMedCrossRef
19.
Zurück zum Zitat Graf W, Dahlberg M, Osman MM et al (1997) Short-term preoperative radiotherapy results in down-staging of rectal cancer: a study of 1316 patients. Radiother Oncol 43:133–137PubMedCrossRef Graf W, Dahlberg M, Osman MM et al (1997) Short-term preoperative radiotherapy results in down-staging of rectal cancer: a study of 1316 patients. Radiother Oncol 43:133–137PubMedCrossRef
20.
Zurück zum Zitat Francois Y, Nemoz CJ, Baulieux J et al (1999) Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial. J Clin Oncol 17:2396PubMed Francois Y, Nemoz CJ, Baulieux J et al (1999) Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial. J Clin Oncol 17:2396PubMed
21.
Zurück zum Zitat Glehen O, Chapet O, Adham M, Nemoz JC, Gerard JP, Lyons Oncology Group (2003) Long-term results of the Lyons R90-01 randomized trial of preoperative radiotherapy with delayed surgery and its effect on sphincter-saving surgery in rectal cancer. Br J Surg 90:996–998PubMedCrossRef Glehen O, Chapet O, Adham M, Nemoz JC, Gerard JP, Lyons Oncology Group (2003) Long-term results of the Lyons R90-01 randomized trial of preoperative radiotherapy with delayed surgery and its effect on sphincter-saving surgery in rectal cancer. Br J Surg 90:996–998PubMedCrossRef
22.
Zurück zum Zitat Garcia-Aguilar J, Smith DD, Avila K, Bergsland EK, Chu P, Krieg RM, Timing of Rectal Cancer Response to Chemoradiation Consortium (2011) Optimal timing of surgery after chemoradiation for advanced rectal cancer: preliminary results of a multicenter, nonrandomized phase II prospective trial. Ann Surg 254:97–102PubMedCentralPubMedCrossRef Garcia-Aguilar J, Smith DD, Avila K, Bergsland EK, Chu P, Krieg RM, Timing of Rectal Cancer Response to Chemoradiation Consortium (2011) Optimal timing of surgery after chemoradiation for advanced rectal cancer: preliminary results of a multicenter, nonrandomized phase II prospective trial. Ann Surg 254:97–102PubMedCentralPubMedCrossRef
23.
Zurück zum Zitat Faria S, Kopek N, Hijal T et al (2014) Phase II trial of short-course radiotherapy followed by delayed surgery for locoregionally advanced rectal cancer. Colorectal Dis 16:66–70CrossRef Faria S, Kopek N, Hijal T et al (2014) Phase II trial of short-course radiotherapy followed by delayed surgery for locoregionally advanced rectal cancer. Colorectal Dis 16:66–70CrossRef
24.
Zurück zum Zitat Appelt AL, Pløen J, Vogelius IR, Bentzen SM, Jakobsen A (2013) Radiation dose–response model for locally advanced rectal cancer after preoperative chemoradiation therapy. Int J Radiat Oncol Biol Phys 85:74–80PubMedCentralPubMedCrossRef Appelt AL, Pløen J, Vogelius IR, Bentzen SM, Jakobsen A (2013) Radiation dose–response model for locally advanced rectal cancer after preoperative chemoradiation therapy. Int J Radiat Oncol Biol Phys 85:74–80PubMedCentralPubMedCrossRef
25.
Zurück zum Zitat Veenhof AA, Kropman RH, Engel AF, Craanen ME, Meijer S et al (2007) Preoperative radiation therapy for locally advanced rectal cancer: a comparison between two different time intervals to surgery. Int J Colorectal Dis 22:507–513PubMedCrossRef Veenhof AA, Kropman RH, Engel AF, Craanen ME, Meijer S et al (2007) Preoperative radiation therapy for locally advanced rectal cancer: a comparison between two different time intervals to surgery. Int J Colorectal Dis 22:507–513PubMedCrossRef
26.
Zurück zum Zitat Ngan SY, Burmeister B, Fisher RJ et al (2012) Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol 30:3827–3833PubMedCrossRef Ngan SY, Burmeister B, Fisher RJ et al (2012) Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol 30:3827–3833PubMedCrossRef
Metadaten
Titel
The timing of surgery after preoperative short-course S-1 chemoradiotherapy with delayed surgery for T3 lower rectal cancer
verfasst von
Naohito Beppu
Nagahide Matsubara
Masashi Noda
Tomoki Yamano
Hiroshi Doi
Norihiko Kamikonya
Naoki Yamanaka
Hidenori Yanagi
Naohiro Tomita
Publikationsdatum
01.12.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
International Journal of Colorectal Disease / Ausgabe 12/2014
Print ISSN: 0179-1958
Elektronische ISSN: 1432-1262
DOI
https://doi.org/10.1007/s00384-014-1997-5

Weitere Artikel der Ausgabe 12/2014

International Journal of Colorectal Disease 12/2014 Zur Ausgabe

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 Ablationstherapie Nachrichten

Nach der Katheterablation von Vorhofflimmern kommt es bei etwa einem Drittel der Patienten zu Rezidiven, meist binnen eines Jahres. Wie sich spätere Rückfälle auf die Erfolgschancen einer erneuten Ablation auswirken, haben Schweizer Kardiologen erforscht.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Ureterstriktur: Innovative OP-Technik bewährt sich

19.04.2024 EAU 2024 Kongressbericht

Die Ureterstriktur ist eine relativ seltene Komplikation, trotzdem bedarf sie einer differenzierten Versorgung. In komplexen Fällen wird dies durch die roboterassistierte OP-Technik gewährleistet. Erste Resultate ermutigen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.